| September 2, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 2, 2025 |
GSK |
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma |
Trial Milestone |
Phase 3 |
| September 2, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 2, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 2, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 2, 2025 |
IONS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 2, 2025 |
ARWR |
8-K filed: Material agreement |
Corporate |
— |
| September 2, 2025 |
ZBIO |
8-K filed: Material agreement, Acquisition completed, Reg FD disclosure |
Corporate |
— |
| September 2, 2025 |
IDYA |
8-K filed: Material agreement |
Corporate |
— |
| September 2, 2025 |
CYTK |
8-K filed: Other event |
Filing |
— |
| September 2, 2025 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| September 2, 2025 |
MLTX |
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa |
Trial Milestone |
Phase 3 |
| September 2, 2025 |
SVRA |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 2, 2025 |
IRD |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 2, 2025 |
OLMA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 2, 2025 |
VOR |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 2, 2025 |
UTHR |
8-K filed: Other event |
Filing |
— |
| September 2, 2025 |
RLMD |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 2, 2025 |
VTVT |
8-K filed: Material agreement |
Corporate |
— |
| September 2, 2025 |
KYNB |
8-K filed: Other event |
Filing |
— |
| September 2, 2025 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| September 2, 2025 |
CATX |
8-K filed: Other event |
Filing |
— |
| September 2, 2025 |
MLYS |
8-K filed: Other event |
Filing |
— |
| September 2, 2025 |
COYA |
8-K filed: Other event |
Filing |
— |
| September 2, 2025 |
CRMD |
8-K filed: Material agreement, Acquisition completed, Leadership change, Reg FD disclosure |
Corporate |
— |
| September 2, 2025 |
OTLK |
8-K filed: Other event |
Filing |
— |
| September 2, 2025 |
EDIT |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 2, 2025 |
MAZE |
8-K filed: Leadership change |
Corporate |
— |
| September 3, 2025 |
AZN |
Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients. |
Trial Milestone |
Phase 4 |
| September 3, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 3, 2025 |
ABBV |
A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088 |
Trial Milestone |
Phase 1 |
| September 3, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| September 3, 2025 |
CYTK |
8-K filed: Other event |
Filing |
— |
| September 3, 2025 |
IMVT |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 3, 2025 |
CABA |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 3, 2025 |
PVLA |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 3, 2025 |
AWHL |
8-K filed: Leadership change |
Corporate |
— |
| September 3, 2025 |
NRIX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 3, 2025 |
ALMS |
8-K filed: Other event |
Filing |
— |
| September 3, 2025 |
KNSA |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 3, 2025 |
GNLX |
8-K filed: Leadership change |
Corporate |
— |
| September 3, 2025 |
BFRI |
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp |
Trial Milestone |
Phase 3 |
| September 3, 2025 |
CATX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 3, 2025 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 3, 2025 |
MLYS |
8-K filed: Other event |
Filing |
— |
| September 3, 2025 |
KYMR |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 3, 2025 |
WVE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 3, 2025 |
PGEN |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| September 3, 2025 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| September 4, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| September 4, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 4, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| September 4, 2025 |
DFTX |
8-K filed: Other event |
Filing |
— |
| September 4, 2025 |
REPL |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 4, 2025 |
BSX |
8-K filed: Leadership change |
Corporate |
— |
| September 4, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 4, 2025 |
MBX |
Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function |
Trial Milestone |
Phase 1 |
| September 4, 2025 |
MBX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 4, 2025 |
CATX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 4, 2025 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| September 4, 2025 |
CGEM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 5, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 5, 2025 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 5, 2025 |
ARWR |
Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis |
Trial Milestone |
Phase 1/Phase 2 |
| September 5, 2025 |
PRAX |
8-K filed: Other event |
Filing |
— |
| September 5, 2025 |
OCGN |
8-K filed: Material agreement |
Corporate |
— |
| September 5, 2025 |
RCUS |
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. |
Trial Milestone |
Phase 1/Phase 2 |
| September 5, 2025 |
CGON |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 5, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| September 5, 2025 |
KYNB |
8-K filed: Acquisition completed |
Corporate |
— |
| September 5, 2025 |
LPCN |
8-K filed: Other event |
Filing |
— |
| September 5, 2025 |
LPCN |
8-K filed: Other event |
Filing |
— |
| September 5, 2025 |
OTLK |
8-K filed: Leadership change |
Corporate |
— |
| September 5, 2025 |
ACRV |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 5, 2025 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| September 5, 2025 |
SXTP |
8-K filed: Material agreement |
Corporate |
— |
| September 5, 2025 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2025 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2025 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2025 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2025 |
RARE |
8-K filed: Other event |
Filing |
— |
| September 8, 2025 |
ALNY |
A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers |
Trial Milestone |
Phase 1 |
| September 8, 2025 |
ALKS |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 8, 2025 |
SMMT |
8-K filed: Other event |
Filing |
— |
| September 8, 2025 |
VSTM |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 8, 2025 |
IDYA |
8-K filed: Other event |
Filing |
— |
| September 8, 2025 |
CYTK |
8-K/A filed: Other event |
Filing |
— |
| September 8, 2025 |
RAPP |
8-K filed: Other event |
Filing |
— |
| September 8, 2025 |
RAPP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 8, 2025 |
DNTH |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 8, 2025 |
BCYC |
8-K filed: Leadership change |
Corporate |
— |
| September 8, 2025 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2025 |
PHVS |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2025 |
ABVX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2025 |
MAIA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 8, 2025 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| September 8, 2025 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 8, 2025 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 9, 2025 |
MRK |
8-K filed: Other event |
Filing |
— |
| September 9, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 9, 2025 |
JNJ |
8-K filed: Leadership change |
Corporate |
— |
| September 9, 2025 |
CGON |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 9, 2025 |
TENX |
8-K filed: Material agreement |
Corporate |
— |
| September 9, 2025 |
AVBP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 9, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| September 9, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| September 9, 2025 |
TCRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 9, 2025 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 9, 2025 |
SXTP |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 10, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| September 10, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 10, 2025 |
NVO |
A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause |
Trial Milestone |
Phase 1 |
| September 10, 2025 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 10, 2025 |
INCY |
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies |
Trial Milestone |
Phase 1 |
| September 10, 2025 |
SVA |
Booster Dose of sIPV Co-administered With MMR and HepA-I. |
Trial Milestone |
Phase 4 |
| September 10, 2025 |
BNTX |
Dose Escalation Trial of BNT152+153 in Patients With Cancer |
Trial Milestone |
Phase 1 |
| September 10, 2025 |
RVMD |
8-K filed: Other event |
Filing |
— |
| September 10, 2025 |
ALNY |
8-K filed: Other event |
Filing |
— |
| September 10, 2025 |
ARWR |
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease |
Trial Milestone |
Phase 1/Phase 2 |
| September 10, 2025 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| September 10, 2025 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| September 10, 2025 |
RAPP |
8-K filed: Material agreement |
Corporate |
— |
| September 10, 2025 |
CORT |
8-K filed: Other event |
Filing |
— |
| September 10, 2025 |
TVTX |
8-K filed: Other event |
Filing |
— |
| September 10, 2025 |
RLMD |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 10, 2025 |
AMLX |
8-K filed: Material agreement |
Corporate |
— |
| September 10, 2025 |
VTVT |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 10, 2025 |
INTS |
8-K filed: Other event |
Filing |
— |
| September 10, 2025 |
ACTU |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 11, 2025 |
BMY |
A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants |
Trial Milestone |
Phase 1 |
| September 11, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 11, 2025 |
ABBV |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 11, 2025 |
ARWR |
8-K filed: Other event |
Filing |
— |
| September 11, 2025 |
KPTI |
8-K filed: Leadership change |
Corporate |
— |
| September 11, 2025 |
URGN |
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer |
Trial Milestone |
Phase 3 |
| September 11, 2025 |
DNTH |
8-K filed: Material agreement |
Corporate |
— |
| September 11, 2025 |
COGT |
8-K filed: Material agreement |
Corporate |
— |
| September 11, 2025 |
ELDN |
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation |
Trial Milestone |
Phase 2 |
| September 11, 2025 |
SLS |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 11, 2025 |
MAIA |
8-K filed: Other event |
Filing |
— |
| September 11, 2025 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 11, 2025 |
ACHV |
8-K filed: Leadership change |
Corporate |
— |
| September 11, 2025 |
HURA |
8-K filed: Material agreement |
Corporate |
— |
| September 11, 2025 |
MAZE |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| September 11, 2025 |
WST |
8-K filed: Leadership change |
Corporate |
— |
| September 12, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 12, 2025 |
ABBV |
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors |
Trial Milestone |
Phase 1 |
| September 12, 2025 |
NVO |
A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants |
Trial Milestone |
Phase 1 |
| September 12, 2025 |
ALNY |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 12, 2025 |
ARWR |
8-K filed: Other event |
Filing |
— |
| September 12, 2025 |
ALKS |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 12, 2025 |
ALKS |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 12, 2025 |
NTLA |
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM) |
Trial Milestone |
Phase 1 |
| September 12, 2025 |
TRVI |
A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants |
Trial Milestone |
Phase 1 |
| September 12, 2025 |
ALXO |
8-K filed: Leadership change, Other event |
Corporate |
— |
| September 12, 2025 |
MAIA |
8-K filed: Other event |
Filing |
— |
| September 12, 2025 |
TRAW |
8-K filed: Material agreement, Acquisition completed |
Corporate |
— |
| September 15, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 15, 2025 |
REPL |
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer |
Trial Milestone |
Phase 2 |
| September 15, 2025 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| September 15, 2025 |
VTGN |
8-K filed: Leadership change |
Corporate |
— |
| September 15, 2025 |
CMPS |
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder |
Trial Milestone |
Phase 2 |
| September 15, 2025 |
NVCR |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 15, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 15, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 15, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| September 15, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 15, 2025 |
EDIT |
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) |
Trial Milestone |
Phase 1/Phase 2 |
| September 15, 2025 |
DRUG |
BMB-101 in Absence Epilepsy and DEE |
Trial Milestone |
Phase 2 |
| September 16, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 16, 2025 |
JNJ |
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors |
Trial Milestone |
Phase 1 |
| September 16, 2025 |
OCGN |
8-K filed: Material agreement |
Corporate |
— |
| September 16, 2025 |
CYTK |
8-K filed: Other event |
Filing |
— |
| September 16, 2025 |
TENX |
8-K filed: Other event |
Filing |
— |
| September 16, 2025 |
CRBP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 16, 2025 |
LYEL |
8-K filed: Leadership change |
Corporate |
— |
| September 16, 2025 |
RLMD |
8-K filed: Other event |
Filing |
— |
| September 16, 2025 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| September 17, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 17, 2025 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| September 17, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 17, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 17, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| September 17, 2025 |
INBS |
8-K filed: Other event |
Filing |
— |
| September 17, 2025 |
VOR |
8-K filed: Other event |
Filing |
— |
| September 17, 2025 |
RLMD |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 17, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 17, 2025 |
XFOR |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| September 18, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 18, 2025 |
SVA |
Phase I Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose) |
Trial Milestone |
Phase 1 |
| September 18, 2025 |
REPL |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 18, 2025 |
HUMA |
8-K filed: Material agreement |
Corporate |
— |
| September 18, 2025 |
NKTR |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 18, 2025 |
AWHL |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 18, 2025 |
GRCE |
8-K filed: Other event |
Filing |
— |
| September 18, 2025 |
MAIA |
8-K filed: Material agreement |
Corporate |
— |
| September 18, 2025 |
CRSP |
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| September 18, 2025 |
RADX |
Results filed (20-F) |
Earnings |
— |
| September 19, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 19, 2025 |
REGN |
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) |
Trial Milestone |
Phase 1 |
| September 19, 2025 |
GILD |
Study of GS-1219 in Participants With HIV-1 |
Trial Milestone |
Phase 1 |
| September 19, 2025 |
COGT |
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis |
Trial Milestone |
Phase 2 |
| September 19, 2025 |
ALMS |
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis |
Trial Milestone |
Phase 3 |
| September 19, 2025 |
RVPH |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| September 20, 2025 |
PFE |
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan |
Trial Milestone |
Phase 3 |
| September 22, 2025 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| September 22, 2025 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| September 22, 2025 |
GSK |
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years |
Trial Milestone |
Phase 1 |
| September 22, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| September 22, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| September 22, 2025 |
IONS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 22, 2025 |
ARWR |
Study of ARO-APOC3 in Adults With Dyslipidemia |
Trial Milestone |
Phase 2 |
| September 22, 2025 |
CYTK |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 22, 2025 |
ORKA |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| September 22, 2025 |
MBX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 22, 2025 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 23, 2025 |
ABBV |
A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder |
Trial Milestone |
Phase 1 |
| September 23, 2025 |
ALMS |
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 |
Trial Milestone |
Phase 3 |
| September 23, 2025 |
SRRK |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 23, 2025 |
BYSI |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 23, 2025 |
AGEN |
8-K filed: Other event |
Filing |
— |
| September 24, 2025 |
PVLA |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 24, 2025 |
IVVD |
8-K filed: Leadership change, Reg FD disclosure, Other event |
Corporate |
— |
| September 24, 2025 |
QURE |
8-K filed: Material agreement |
Corporate |
— |
| September 24, 2025 |
QURE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 24, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| September 24, 2025 |
IMRX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 24, 2025 |
MAIA |
8-K filed: Other event |
Filing |
— |
| September 24, 2025 |
WVE |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 25, 2025 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| September 25, 2025 |
JNJ |
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma |
Trial Milestone |
Phase 1 |
| September 25, 2025 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 25, 2025 |
INBS |
8-K filed: Other event |
Filing |
— |
| September 25, 2025 |
MRNA |
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) |
Trial Milestone |
Phase 2 |
| September 25, 2025 |
NTLA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 25, 2025 |
IMUX |
8-K filed: Other event |
Filing |
— |
| September 25, 2025 |
AWHL |
8-K filed: Material agreement |
Corporate |
— |
| September 25, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| September 25, 2025 |
IMRX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 25, 2025 |
KYTX |
8-K filed: Leadership change |
Corporate |
— |
| September 25, 2025 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 25, 2025 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| September 26, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| September 26, 2025 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| September 26, 2025 |
RAPP |
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy |
Trial Milestone |
Phase 2 |
| September 26, 2025 |
MBX |
8-K filed: Material agreement |
Corporate |
— |
| September 26, 2025 |
SMNR |
8-K filed: Material agreement, Acquisition completed, Leadership change, Reg FD disclosure, Other event |
Corporate |
— |
| September 26, 2025 |
LPCN |
8-K filed: Other event |
Filing |
— |
| September 29, 2025 |
AZN |
A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity |
Trial Milestone |
Phase 1 |
| September 29, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2025 |
INCY |
A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants |
Trial Milestone |
Phase 1 |
| September 29, 2025 |
GRFS |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2025 |
MLTX |
8-K filed: Other event |
Filing |
— |
| September 29, 2025 |
ANVS |
8-K filed: Leadership change |
Corporate |
— |
| September 29, 2025 |
MDWD |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2025 |
QURE |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 29, 2025 |
LRMR |
8-K filed: Other event |
Filing |
— |
| September 29, 2025 |
CLYM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 29, 2025 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2025 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 29, 2025 |
ACHV |
Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers |
Trial Milestone |
Phase 3 |
| September 29, 2025 |
OTLK |
8-K filed: Other event |
Filing |
— |
| September 30, 2025 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| September 30, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| September 30, 2025 |
ALNY |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects |
Trial Milestone |
Phase 1 |
| September 30, 2025 |
INSM |
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) |
Trial Milestone |
Phase 2 |
| September 30, 2025 |
OCUL |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 30, 2025 |
OCUL |
8-K filed: Other event |
Filing |
— |
| September 30, 2025 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| September 30, 2025 |
PCVX |
8-K filed: Material agreement |
Corporate |
— |
| September 30, 2025 |
MDWD |
6-K filed: Foreign issuer report |
Filing |
— |
| September 30, 2025 |
COGT |
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors |
Trial Milestone |
Phase 3 |
| September 30, 2025 |
IRD |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| September 30, 2025 |
AMLX |
AMX0035 and Progressive Supranuclear Palsy |
Trial Milestone |
Phase 2/Phase 3 |
| September 30, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| September 30, 2025 |
MAIA |
8-K filed: Material agreement, Other event |
Corporate |
— |
| September 30, 2025 |
ABEO |
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients |
Trial Milestone |
Phase 3 |
| September 30, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| September 30, 2025 |
LPCN |
8-K filed: Other event |
Filing |
— |